A Letter to the Editor on "Reducing the Risk of Developing Diabetes: The Role of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors in Patients with Hypertension Combined Prediabetes". [PDF]
Khan G.
europepmc +1 more source
Abstract Aims Sodium‐glucose co‐transporter 2 inhibitors have demonstrated cardiovascular benefits in individuals with type 2 diabetes mellitus, but the optimal timing of initiation in those with acute coronary syndrome is not known. This study aims to assess if early therapy at discharge is superior to delayed or no therapy in reduction in major ...
Muhammad Usman Shah +7 more
wiley +1 more source
ABSTRACT Aim To compare kidney outcomes after GLP‐1 receptor agonists (RA) or tirzepatide (GLP‐1/GIP RAs) versus finerenone initiation in adults with Type 2 diabetes (T2D) and moderate chronic kidney disease (CKD). Methods In a retrospective TriNetX global network study (July 2021–November 2025), adults with T2D and CKD stages 3–4 initiating GLP‐1/GIP ...
Dvora R. Sehtman‐Shachar +5 more
wiley +1 more source
Prognostic impact of angiotensin-converting enzyme inhibitors and dexmedetomidine in acute respiratory distress syndrome: a MIMIC-IV-based retrospective cohort analysis. [PDF]
Hong Q +5 more
europepmc +1 more source
ABSTRACT Aims To assess changes in glycated haemoglobin (HbA1c), body weight, and systolic/diastolic blood pressure (SBP/DBP) by chronic kidney disease (CKD) and albuminuria categories in a post hoc analysis of FLOW, an international, double‐blind, randomized, phase 3b clinical trial of adults with CKD and Type 2 diabetes (T2D).
Allon N. Friedman +10 more
wiley +1 more source
Withholding vs. continuing angiotensin-converting enzyme inhibitors or angiotensin receptor blockers before surgery: a systematic review and meta-analysis of randomized controlled trials. [PDF]
Dou W +6 more
europepmc +1 more source
ABSTRACT Introduction Autonomic dysfunction increases the risk of cardio‐kidney‐metabolic (CKM) syndrome including metabolic dysfunction‐associated steatotic liver disease (MASLD), type 2 diabetes (T2D), cardiovascular disease (CVD) and chronic kidney disease (CKD).
Alex E. Henney +8 more
wiley +1 more source
COVID-19 Pandemic Waves and 2024-2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine. [PDF]
Puigdellívol-Sánchez A +10 more
europepmc +1 more source
Metformin and Severe Post‐COVID‐19 Outcomes Among Individuals With Diabetes Mellitus
ABSTRACT Aims We evaluated the relationship between metformin, one of the most commonly prescribed medications for individuals with diabetes, and COVID‐19 sequelae. Materials and Methods We evaluated a retrospective cohort of individuals in the National Clinical Cohort Collaborative with Type 2 diabetes mellitus and COVID‐19 who were prescribed ...
Zachary B. Dozier +148 more
wiley +1 more source
Comparative Risk Assessment in Hypertensive Patients With Metabolic Syndrome by Exploring Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. [PDF]
Khan MH +6 more
europepmc +1 more source

